Angelini Ventures Invests in Hypervision Surgical’s £17 Million Series A

Angelini Ventures has participated in Hypervision Surgical’s £17 million Series A funding round, aimed at advancing the company’s Hyperspectral Intelligence® platform for AI-assisted surgery. The funding will facilitate commercial deployment and clinical adoption of advanced hyperspectral imaging technology that provides real-time insights into tissue physiology during surgeries. The investment, led by Heal Capital, also includes participation from various other investors and strategic partners, indicating strong confidence in Hypervision’s potential to improve surgical outcomes and patient safety.